ClinicalTrials.gov
ClinicalTrials.gov Menu

The STRIVE Study: Breast Cancer Screening Cohort

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03085888
Recruitment Status : Enrolling by invitation
First Posted : March 21, 2017
Last Update Posted : July 13, 2018
Sponsor:
Information provided by (Responsible Party):
GRAIL, Inc.

Brief Summary:
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to train and validate an assay to detect invasive breast cancer in patients undergoing mammography.

Condition or disease
Invasive Breast Cancer Neoplasm, Breast Cancer, Breast

Detailed Description:
Detection of early stage cancer may be possible through analysis of circulating cell-free nucleic acids (cfNAs) shed into the blood by tumors. GRAIL is using high-intensity sequencing (based on broad genomic coverage and deep sequencing) of cfNAs, combined with machine learning, to develop blood tests to detect cancer early. The purpose of this prospective, multi-center, observational cohort study is to train and validate an assay for the early detection of breast cancer. The study will collect blood samples from participants within 28 days of their screening mammogram. Additional blood samples will also be collected for a subset of participants. For participants who receive a cancer diagnosis during the study, tissue samples will be collected.

Study Type : Observational [Patient Registry]
Estimated Enrollment : 120000 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Actual Study Start Date : February 28, 2017
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : May 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Group/Cohort
Prospective Cohort
This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.



Primary Outcome Measures :
  1. Diagnosis of invasive breast cancer among women undergoing mammography [ Time Frame: 30 Months Estimated ]
    Clinically annotated plasma samples from participants will undergo high-intensity sequencing to characterize cfNA profiles.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
This study seeks to enroll 120,000 women undergoing mammography for screening indications and associated medical care from participating study centers.
Criteria

Inclusion Criteria:

  1. Women undergoing mammography for screening indications or have an appointment for screening mammography.
  2. Participant provides informed consent and expresses understanding of the protocol and its requirements, risks, and discomforts.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03085888


  Show 33 Study Locations
Sponsors and Collaborators
GRAIL, Inc.
Investigators
Study Director: Brian Allen, MS GRAIL, Inc.
Study Director: Anne-Renee Hartman, MD GRAIL, Inc.

Responsible Party: GRAIL, Inc.
ClinicalTrials.gov Identifier: NCT03085888     History of Changes
Other Study ID Numbers: GRAIL-002
First Posted: March 21, 2017    Key Record Dates
Last Update Posted: July 13, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by GRAIL, Inc.:
Cancer Screening
Next Generation Sequencing
Circulating cell-free nucleic acid
Circulating cell-free tumor DNA
Deep sequencing

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases